BridgeBio Pharma, Inc.
Industry Group: Pharmaceuticals
Country/Region: United States of America
Identifier: NAS:BBIO
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy. The company focus on genetic diseases because they exist at the intersection of high unmet patient need and tractable biology.
ESG Risk Rating
Ranking
Industry Group (1st = lowest risk)
Pharmaceuticals 792 out of 928
Universe
Global Universe 14100 out of 16421
What are the ESG Risk Ratings?
Notice: The information is provided as is, for informational, non-commercial purposes only, does not constitute investment advice and is subject to conditions available in our Legal Disclaimer. They are not directed to, or intended for distribution to or use by India-based clients or users and their distribution to Indian resident individuals or entities is not permitted. Usage of this information is not permitted in any way, unless otherwise agreed in writing. By way of exception, usage of this information is permitted to the rated subject, limited to a single reference to the score on the rated subject’s sustainability webpage or CSR report, mentioning Sustainalytics as a source. For referencing Sustainalytics please consult the Company Guide.
Industry Comparison
Company | ESG Risk Rating | Industry Rank |
---|---|---|
H. Lundbeck A/S |
20.4
Medium
|
90 out of 928 |
Organon & Co. |
25.3
Medium
|
225 out of 928 |
SK Biopharmaceuticals Co., Ltd. |
29.1
Medium
|
481 out of 928 |
BridgeBio Pharma, Inc. |
35.7
High
|
792 out of 928 |
Shenzhen Salubris Pharmaceuticals Co., Ltd. |
38.5
High
|
869 out of 928 |
For corporate professionals interested in direct competitor insights
Sustainalytics' Peer Performance Insights gives an in-depth analysis of your company's ESG strengths and weaknesses compared to your competitors and industry performance. These insights can be used to identify areas of ESG improvement to help inform future management decisions that align with your organization's sustainability goals.
Our Approach to Calculating ESG Risk
The ESG Risk Ratings measure a company's exposure to industry-specific material ESG risks and how well a company is managing those risks.
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues. Our exposure score takes into consideration subindustry and company-specific factors such as its business model.
BridgeBio Pharma, Inc.'s Exposure is Medium
Management
Management refers to how well a company is managing its relevant ESG issues. Our management score assesses the robustness of a company's ESG programs, practices and policies.
BridgeBio Pharma, Inc.'s Management of ESG Material Risk is Average
How do the ESG Risk Ratings work?
Controversy Rating
Highest Controversy level that has impacted BridgeBio Pharma, Inc.'s ESG Risk Rating in the last three years
Highest Controversy Level